NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its second quarter revenues for fiscal year 2015 declined 10 percent year over year.

Myriad also substantially lowered its guidance for Fiscal Year 2015, leading to a drop in its stock on Wednesday morning.

For the three months ended Dec. 31, the Salt Lake City-based molecular diagnostics firm had total revenues of $184.4 million compared to revenues of $204.1 million in Q2 2014. The revenues beat the consensus Wall Street estimate of $183.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.